insomnia

Ramelteon (TAK-375) is a Melatonin Receptor Agonist. The mechanism of action of ramelteon is as a Melatonin Receptor Agonist.

Clomethiazole (Distraneurin) is an orally active GABAA agonist and it is an anticonvulsant agent. It also has the potential for treating convulsive status epilepticus. Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes.

pCPA methyl ester hydrochloride (4-Chloro-DL-phenylalanine methyl ester hydrochloride) is an inhibitor of tryptophan hydroxylase inhibitor and 5-HT synthesis. pCPA methyl ester hydrochloride is permeable across the blood-brain barrier and reduces 5-HT central availability.

Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain. Seltorexant is a high-affinity and selective orexin-2 receptor antagonist (pKi: 8.0 and 8.1 for human and rat OX2R).

MK-1064 (Urokinase inhibitor 1) is a selective orexin 2 receptor antagonist (2-SORA).

6-Chloromelatonin is a potent melatonin receptor agonist, a 5-methoxyindole compound that competes for presynaptic melatonin receptor sites in the rabbit retina, inhibiting the calcium-dependent release of [3H]dopamine with higher metabolic stability than melatonin. Chloromelatonin competitively binds to [3H]melatonin at MT2 receptors (pKi=9.77) and may be used to study insomnia and sleep disorders associated with depression.

Atagabalin HCl is a novel voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) ligand that affects slow-wave sleep and can be used to treat insomnia.

Lopirazepam is a potent small molecule GABAA receptor agonist, which can be used to treat anxiety disorders, insomnia, epilepsy and other diseases.

D-Ornithine monohydrochloride is an endogenous metabolite that regulates intramuscular hormone levels, and has been used in studies of dry skin and insomnia.3,5-Dihydroxybenzoic acid is an endogenous metabolite that regulates intramuscular hormone levels.

Trazodone hydrochloride (Trazodone HCl) is a serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety.

Atagabalin, also known as PD 0200390, is a gabamimetic agent under development for the treatment for insomnia. Atagabalin is related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was discontinued following unsatisfactory t

Doxepin-D3 hydrochloride is a deuterium-labeled, stable isotope-labeled analogue of doxepin hydrochloride, primarily used as an internal standard for quantitative analysis. Doxepin hydrochloride (T1540) is a tricyclic antidepressant (TCA) and uesd for treating depression, anxiety, and insomnia.

Toladryl is a derivative of Diphenhydramine that can cross the blood-brain barrier and exhibits oral activity, with antihistamine and anticholinergic properties. Its anticholinergic effects are approximately a tenth of those seen with Diphenhydramine, yet it offers 2-4 times the protection against lethal doses of histamine in guinea pigs. The side effects of Toladryl are fewer and milder compared to Diphenhydramine; however, at higher doses, it may cause symptoms such as insomnia, agitation, and disorientation related to the central nervous system. Toladryl is utilized in the research of allergic diseases.

Benzobarbital is utilized in the treatment of convulsive forms of epilepsy, hemolytic disease of the newborn, and insomnia.

Heptabarbital (Medomin) is an orally active derivative of barbituric acid with potential research applications for insomnia.

Fumiporexant (Compound Example 93) is an orally active, brain-penetrant, and selective antagonist of orexin receptor 2 (OX2R). It regulates the sleep-wake cycle and pathways related to mood in the central nervous system. Fumiporexant holds potential for research into neurological disorders such as insomnia and major depressive disorder.

Propiomazine maleate is an orally active antihistamine. It acts as a potent stimulant for prolactin (PRL) release through antagonism of the dopaminergic system and inhibits luteinizing hormone (LH) secretion. Propiomazine maleate is primarily utilized as an adjunct in anesthesia, in the management of psychiatric disorders and anxiety sedation, and is also used in research related to insomnia.

Sunobinop (S 117957) TFA is an orally active and blood-brain barrier-penetrating selective partial agonist of the human nociceptin/orphanin FQ peptide receptor (NOP), with high affinity for human targets (Ki=3.3 nM; EC50=4.03 nM; Emax=47.8%), without activating μ and κ opioid receptors. In rats, Sunobinop TFA significantly reduces wakefulness and increases non-rapid eye movement (NREM) sleep through NOP receptor activation, without significant side effects on learning, memory, reward, respiration, or intestinal function at effective doses. It also displays competitive antagonist properties in certain signaling pathways [such as β-Arrestin 2 recruitment]. Sunobinop TFA can be employed in research involving insomnia, moderate to severe alcohol use disorder, and incontinence due to bladder overactivity.

Lobelin sulphate is an alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has a variety of therapeutic uses including in insomnia, and smoking cessation, peripheral vascular disorders, respiratory disor

Pruvanserin hydrochloride (EMD 281014 HCl) is an inverse and selective 5-HT2A receptor antagonist with IC₅₀ values of 0.35 nM and 1 nM for human and rat 5-HT2A receptors, respectively. Pruvanserin hydrochloride inhibits GTP-gamma-S accumulation and alleviates tactile allodynia in diabetic rats, making it suitable for studies on Parkinson's disease, insomnia, and schizophrenia.

Triclofos Sodium is used to treat insomnia and used for sedation.

Lobeline, (+)- is an alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, a

N-Desmethyl Pimavanserin (AC-279) is the active metabolite of Pimavanserin, a 5-HT2A receptor inverse agonist, which is used in the treatment of sleep disorders such as insomnia.

Orexin Receptor Antagonist 2 (compound 30), characterized by its potent antagonistic activity with pKis of 7.69 and 9.78, holds promise for insomnia research[1].